UCB has announced new clinical data that demonstrates the prolonged benefits offered by its drug Cimzia in the treatment of axial spondyloarthritis.

Four-year imaging results from an extension study of the phase III trial RAPID-axSpA, which involved both ankylosing spondylitis and non-radiographic axial spondyloarthritis patients, showed that Cimzia was associated with limited spinal radiographic progression, especially between weeks 96 and 204.

“UCB has announced four-year imaging results showing the long-term efficacy of Cimzia in patients with axial spondyloarthritis.“

The use of UCB's therapy also resulted in limited changes in radiographic sacroiliitis and maintenance of early reductions of inflammation of the spine and sacroiliac joints through the duration of the study.

Long-term disease control through the suppression of inflammation and prevention or slowing of new bone formation is a major treatment goal for this condition, with this study showing that Cimzia can be a valuable tool in this regard.

Emmanuel Caeymaex, head of immunology and executive vice-president for the immunology patient value unit at UCB, said: "We are committed to this kind of sustained and focused research for diseases as complex as axial spondyloarthritis, because it is the only way to reach the most patients with appropriate therapies that meaningfully improve their lives."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.